Theraclone Sciences
Seattle, US · Delaware corporation · 1 known investors
Biotech
Founders & leadership
KS
Kristine SwiderekExecutive
RH
Russ HawkinsonExecutive
CS
Clifford StocksExecutive
Board
SG
Steven GillisBoard director
WH
CM
Christopher MirabelliBoard director
WR
Wendye RobbinsBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$3.1M disclosed across 1 round · 2015
▶$3.1MraisedMay 2015 · 12 investors · BiotechnologyRule 506(b)
▶$3.1MraisedMay 2015 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven GillisExecutive Officer, Director
- Kristine SwiderekExecutive Officer
- Wende HuttonDirector
- Russ HawkinsonExecutive Officer
- Wendye RobbinsDirector
- Clifford StocksExecutive Officer, Director
- Christopher MirabelliDirector
- Offering amount
- $4.4M
- Amount sold
- $3.1M
- First sale
- Apr 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Theraclone Sciences's investors?
- Theraclone Sciences's investors include Canaan Partners.
- How much funding has Theraclone Sciences raised?
- Theraclone Sciences has disclosed $3.1M raised across 1 round.
- Where is Theraclone Sciences headquartered?
- Theraclone Sciences is headquartered in Seattle, US.